Acute PancreatitisPAN-PROMISENCT03650062
Patient-reported Outcome Scale in Acute Pancreatitis
An observational study of Acute Pancreatitis, run by Enrique de-Madaria at 26 sites in 14 countries.
Trial summary
The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based in the patient´s experience. PAN-PROMISE is a cohort study involving patients with AP. Read more about this study
- Who is it for?
- Ages 18 to 79 years
- Conditions the study is for
- Acute Pancreatitis
- How many people
- 525 participants
- Where
- 26 sitesin 14 countries
- Study dates
- 30 May 2017to 3 Feb 2019
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- Adult, Older adult
Study population: Consecutive patients admitted with acute pancreatitis in the participating centers.
Who may be able to join
- Patients ≥18 and <80 years.
- Karnofsky performance status previous to AP 100 (normal, no complaints, no evidence of disease), 90 (able to carry on normal activity; minor signs or symptoms of disease) or 80 (normal activity with effort; some signs or symptoms of disease).
- Acute pancreatitis defined as at least 2 of the following 3 criteria: A) Typical abdominal pain, B) Elevation of amylase and/or lipase more than 3 times the upper limit of normality, and C) Imaging (preferably CT and/or MR) compatible with AP.
- Written informed consent.
Who cannot join
- Time between onset of symptoms and presentation in the emergency room (ER) greater than 48 hours (we do not consider as onset of symptoms previous self-limited heraldic biliary pain)
- Recruitment >24h after presentation in the ER
- Karnofsky performance status previous to AP 70 (Cares for self; unable to carry on normal activity or to do active work) or less
- Inability to express or understand the instructions of the study (severe congenital or acquired intellectual deficit).
- More than 1 previous episode of AP.
- Chronic pancreatitis.
- Presence of diseases or conditions different from AP that may interfere with the scale: other causes of abdominal pain (especially acute cholecystitis; Note: choledocholithiasis-acute cholangitis is not an exclusion criteria), obstruction of the digestive tract (peptic pyloric stenosis, gastrointestinal anastomotic stenosis, diabetic gastroparesis, gastrointestinal neoplasia...), nausea-vomiting (brain tumor, chemotherapy...) or weakness (pre-existing anemia with Hb <9 mg/dL, heart failure or respiratory insufficiency associated with minimal effort dyspnea, or domiciliary treatment with O2, advanced neoplasms or other debilitating diseases).
Trial locations and contacts
26 sites in 14 countries.
26 sites in 14 countries
Spain10 sites
Hospital General Universitario de Alicante
Alicante, 03550
Hospital Santa María
Lleida
Hospital San Pedro
Logroño
Hospital Central de Asturias
Oviedo
Complejo Hospitalario de Navarra
Pamplona
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela
Hospital Clínico Universitario de Valladolid
Valladolid
Hospital Alvaro Cunqueiro
Vigo
Hospital Lozano Blesa
Zaragoza
Hospital Miguel Servet
Zaragoza
Hungary2 sites
Centre for Translational Medicine, University of Pécs
Pécs
University of Szeged
Szeged
Portugal2 sites
Fernando Fonseca Hospital
Amadora
Centro Hospitalar Tondela-Viseu
Viseu
Romania2 sites
Emergency Hospital of Bucharest
Bucharest
Iuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca
United States1 site
Johns Hopkins Medical Center
Baltimore, Maryland, 21287
About this study
Official title: Patient-reported Outcome Scale in Acute pancreatitis-an International Prospective Cohort Study
The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based in the patient´s experience. PAN-PROMISE is a cohort study involving patients with AP. The patient´s symptom perception will be compared with the opinion of the clinicians and with clinical outcomes.
Read the detailed description
Currently, the most important outcome variables in Acute Pancreatitis (AP) are persistent organ failure (POF) and mortality, according to the physician point of view. These variables occur infrequently (<10 and <5% respectively) (Sternby et all, see "References"), therefore, studies designed to assess the effectiveness of new treatments for AP to decrease POF or mortality require a very large sample of patients, which is unfeasible. Currently, clinical trials addressing the management of AP do not take into account Patient Reported Outcome Measures.
PROMS (Patient Reported Outcome Measures) have been defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else (first link in "References"). PROMS are gaining importance as a tool to design outcome variables. This kind of measurement has been recently included in the quality assesment approaches (Crossing the Quality Chasm: A New Health System for the 21st Century, see "References"), being PROMS a useful tool to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience (second link in "References"). The aim of PAN-PROMISE is to incorporate an outcome variable in AP based in the patient´s experience. For this purpose the investigators involved in this project have developed a new instrument based on symptoms found to be important for the patient. This new instrument is intended to be a simple quantitative variable, relevant for the patient, that can be useful to test new treatments for AP without the need for a very large sample size, fulfilling the requirements of the triple aim framework by incorporating an outcome measurement defined by the patient.
Hypothesis:
- PROMS must be incorporated to patient care and research in AP to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience
- A PROMS scale is a useful outcome variable to investigate new treatments in AP
- The different severity categories of the revision of the Atlanta Classification (RAC) have different scores on the PROMS scale in acute pancreatitis: severe greater than moderate and mild, moderate greater than mild.
- Increasing scores on the PROMS scale are associated to increased morbidity
Aims:
- Main aim 1: to measure patient´s symptoms during an episode of AP and to correlate the intensity of these symptoms to clinical outcomes
- Main aim 2: to design and validate a PROMS scale in AP intended to be an suitable outcome variable in future trials addressing the management of AP
Methods
Part 1: development of the PAN-PROMISE instrument The PAN-PROMISE research team developed a qualitative study in which three nominal groups were conducted, two with patients who had suffered an acute pancreatitis (AP) in hospitals in Alicante (Universitarian General Hospital)), and Valencia (Clinic Hospital), Spain and another with clinicians from the Alicante region with experience in treating patients with AP. Participants were asked about the symptoms that cause the most discomfort and concern to patients at three specific times: before receiving treatment for AP, during hospital admission and after discharge. The perspectives of patients and professionals were compared. From the information gathered in the nominal groups, a first version of a PROMS questionnaire was elaborated and shared with an international group of gastroenterologists, experienced in the management of pancreatitis, from 4 countries (Germany, Spain, USA, India and Turkey) through an online application to determine to what extent these experiences were shared in frequency and intensity by patients in these different countries. With all this information, a PROMS instrument was generated.
Part 2: measurement of patient´s symptoms in an international cohort study
2.1 Design. The PAN-PROMISE instrument is being measured in patients participating in a multicenter international prospective cohort study. Consecutive adult patients with AP are eligible after signed informed consent.
2.2 Center recruitment The PAN-PROMISE study has been endorsed by the Spanish Association of Pancreatology (AESPANC), the Spanish Association of Gastroenterology (AEG) and the International Association of Pancreatology (IAP); these associations shared the project with their members and through their social networks, calling for researchers and centers to join this initiative. PAN-PROMISE has also a webpage www.promisepancreatitis.com to promote center recruitment.
2.3 Patient registry PAN-PROMISE measurement will rely on a patient registry hosted in the Spanish Association of Gastroenterology (AEG) REDCap node. AEG offered this REDCap web-based online patient registry tool at no cost. Claudia Sánchez-Marin, a gastroenterologist, is on charge of quality control (data validation, data checks, contact with researchers to solve issues). The REDCap online registry was designed with logical rules to ensure good quality data entry, including mandatory fields to enter, logical ranges for quantitative variables, alarms if logical rules are not coherent (for example to have persistent organ failure but to classify the episode as mild or moderate), expanding fields only available in the presence of certain circumstances (for example, detailed organ failure description is only available if the patient had organ failure).
- Conditions
- Acute Pancreatitis
- Keywords
- Patient Reported Outcome Measures, Follow-Up Studies, Patient Outcome Assessment, Treatment Outcome, Pancreatitis, Acute Necrotizing
- Medical subject headings
- Pancreatitis, Pancreatitis, Acute Necrotizing
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications]
Mild acute pancreatitis (no complications), moderately severe acute pancreatitis (local complications and/or transient (≤48h) organ failure and/or exacerbation of previous comorbidity), severe acute pancreatitis (persistent (>48h) organ failure) (see revised Atlanta classification, Banks et al, Gut 2013)
Measured: Up to 15 days after hospital discharge from index hospital admission
PAN-PROMISE patient reported outcome measurement instrument
PROMISE SCALE (Patient-reported Outcome Scale in Acute pancreatitis) Each item is scored from 0 to 10 ( worst score in the last 24h): 0 none, 10: the highest possible intensity according to the patient
- Pain, especially in the abdomen, chest or back
- Abdominal distention (bloating, sensation of excess gas)
- Difficulty eating, sensation of food being stuck in the stomach
- Difficulty with bowel movements (constipation or straining on bowel movements)
- Nausea and/or vomiting
- Thirst
- Weakness, lack of energy, fatigue, difficulty moving
Measured: From within 24h after admission to 15 days after discharge
Secondary outcomes (11)
EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30) Version 3.0
EORTC QLQ-C30, a widely used and validated quality of life scale, includes 28 questions with a four-point scale: "Not at all" (1 point), "A little" (2), "Quite a bit" (3) and "Very much." (4); 4 means an important impact on quality of life. The last 2 questions are scored from 1 (very poor) to 7 (excellent), being 7 indicative of excellent quality of life.
Measured: 15 days after hospital discharge
C-reactive protein
A marker of inflammation
Measured: 48 and 72h after recruitment
Local complications (incidence of pancreatic/peripancreatic necrosis and acute peripancreatic fluid collections)
Defined according to the revised Atlanta classification (Banks et al, Gut 2013)
Measured: Up to 15 days after hospital discharge from index hospital admission
Need for invasive treatment
Endoscopic, percutaneous or surgical drainage or necrosectomy
Measured: Up to 15 days after hospital discharge from index hospital admission
Need for nutritional support
Need for enteral and/or parenteral nutritional support
Measured: Up to 15 days after hospital discharge from index hospital admission
Admission in the Intensive Care Unit
Need for intensive care support
Measured: Up to 15 days after hospital discharge from index hospital admission
Hospital stay
Days, on index admission
Measured: Up to 15 days after hospital discharge from index hospital admission
Organ failure
Transient and persistent organ failure defined according to the revised Atlanta classification (Banks et al, Gut 2013)
Measured: Up to 15 days after hospital discharge from index hospital admission
Mortality
Mortality during index admission
Measured: Up to 15 days after hospital discharge from index hospital admission
Hospital readmission
Hospital readmission due to symptom relapse or complications of index acute pancreatitis
Measured: Up to 15 days after hospital discharge from index hospital admission
Systemic Inflammatory Response Syndrome (SIRS)
Presence of SIRS and persistent (>48h) SIRS
Measured: Up to 15 days after hospital discharge from index hospital admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2018
- Study start30 May 2017
- Primary completion3 Feb 2019
- Study completion3 Feb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute PancreatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 525 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Enrique de-Madaria
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Enrique de-Madaria, Hospital General Universitario de Alicante
- Investigators
- José Joaquín Mira, PsyD PhD, Study director, Universidad Miguel Hernandez de ElcheEnrique de-Madaria, MD PhD, Principal investigator, Hospital General Universitario de Alicante
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03650062
- Sponsor's protocol ID
- PI2016/69
- Acronym
- PAN-PROMISE
- Status last verified
- Feb 2019
- First submitted
- 20 Aug 2018
- Last updated
- 5 Feb 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The whole database will be offered to the study collaborators who actively recruited patients
Publications
Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001. Available from http://www.ncbi.nlm.nih.gov/books/NBK222274/
PubMed 25057539Sternby H, Bolado F, Canaval-Zuleta HJ, Marra-Lopez C, Hernando-Alonso AI, Del-Val-Antonana A, Garcia-Rayado G, Rivera-Irigoin R, Grau-Garcia FJ, Oms L, Millastre-Bocos J, Pascual-Moreno I, Martinez-Ares D, Rodriguez-Oballe JA, Lopez-Serrano A, Ruiz-Rebollo ML, Viejo-Almanzor A, Gonzalez-de-la-Higuera B, Orive-Calzada A, Gomez-Anta I, Pamies-Guilabert J, Fernandez-Gutierrez-Del-Alamo F, Iranzo-Gonzalez-Cruz I, Perez-Munante ME, Esteba MD, Pardillos-Tome A, Zapater P, de-Madaria E. Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study. Ann Surg. 2019 Aug;270(2):348-355. doi: 10.1097/SLA.0000000000002766.
PubMed 29672416de-Madaria E, Sanchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Marta K, Kamal A, Lauret-Brana E, Barbu ST, Nunes V, Ruiz-Rebollo ML, Garcia-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ. Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut. 2021 Jan;70(1):139-147. doi: 10.1136/gutjnl-2020-320729. Epub 2020 Apr 3.
PubMed 32245906
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient-reported Outcome Scale in Acute pancreatitis-an International Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT03650062
- Acronym / sponsor ID
- PAN-PROMISE / PI2016/69
- Conditions
- Acute Pancreatitis
- Keywords
- Patient Reported Outcome Measures, Follow-Up Studies, Patient Outcome Assessment, Treatment Outcome, Pancreatitis, Acute Necrotizing
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 525 participants (actual)
- Lead sponsor
- Enrique de-MadariaUniversity, hospital or other
- Study start
- 30 May 2017 (actual)
- Primary completion
- 3 Feb 2019 (actual)
- Study completion
- 3 Feb 2019 (actual)
- First posted
- 28 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The PAN-PROMISE study (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis-an international proSpEctive cohort study) aims to measure an outcome variable in acute pancreatitis (AP) based in the patient´s experience. PAN-PROMISE is a cohort study involving patients with AP. The patient´s symptom perception will be compared with the opinion of the clinicians and with clinical outcomes.
Detailed description
Currently, the most important outcome variables in Acute Pancreatitis (AP) are persistent organ failure (POF) and mortality, according to the physician point of view. These variables occur infrequently (<10 and <5% respectively) (Sternby et all, see "References"), therefore, studies designed to assess the effectiveness of new treatments for AP to decrease POF or mortality require a very large sample of patients, which is unfeasible. Currently, clinical trials addressing the management of AP do not take into account Patient Reported Outcome Measures.
PROMS (Patient Reported Outcome Measures) have been defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else (first link in "References"). PROMS are gaining importance as a tool to design outcome variables. This kind of measurement has been recently included in the quality assesment approaches (Crossing the Quality Chasm: A New Health System for the 21st Century, see "References"), being PROMS a useful tool to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience (second link in "References"). The aim of PAN-PROMISE is to incorporate an outcome variable in AP based in the patient´s experience. For this purpose the investigators involved in this project have developed a new instrument based on symptoms found to be important for the patient. This new instrument is intended to be a simple quantitative variable, relevant for the patient, that can be useful to test new treatments for AP without the need for a very large sample size, fulfilling the requirements of the triple aim framework by incorporating an outcome measurement defined by the patient.
Hypothesis:
- PROMS must be incorporated to patient care and research in AP to improve the triple aim framework of better quality, appropriate utilization, and enhanced patient experience
- A PROMS scale is a useful outcome variable to investigate new treatments in AP
- The different severity categories of the revision of the Atlanta Classification (RAC) have different scores on the PROMS scale in acute pancreatitis: severe greater than moderate and mild, moderate greater than mild.
- Increasing scores on the PROMS scale are associated to increased morbidity
Aims:
- Main aim 1: to measure patient´s symptoms during an episode of AP and to correlate the intensity of these symptoms to clinical outcomes
- Main aim 2: to design and validate a PROMS scale in AP intended to be an suitable outcome variable in future trials addressing the management of AP
Methods
Part 1: development of the PAN-PROMISE instrument The PAN-PROMISE research team developed a qualitative study in which three nominal groups were conducted, two with patients who had suffered an acute pancreatitis (AP) in hospitals in Alicante (Universitarian General Hospital)), and Valencia (Clinic Hospital), Spain and another with clinicians from the Alicante region with experience in treating patients with AP. Participants were asked about the symptoms that cause the most discomfort and concern to patients at three specific times: before receiving treatment for AP, during hospital admission and after discharge. The perspectives of patients and professionals were compared. From the information gathered in the nominal groups, a first version of a PROMS questionnaire was elaborated and shared with an international group of gastroenterologists, experienced in the management of pancreatitis, from 4 countries (Germany, Spain, USA, India and Turkey) through an online application to determine to what extent these experiences were shared in frequency and intensity by patients in these different countries. With all this information, a PROMS instrument was generated.
Part 2: measurement of patient´s symptoms in an international cohort study
2.1 Design. The PAN-PROMISE instrument is being measured in patients participating in a multicenter international prospective cohort study. Consecutive adult patients with AP are eligible after signed informed consent.
2.2 Center recruitment The PAN-PROMISE study has been endorsed by the Spanish Association of Pancreatology (AESPANC), the Spanish Association of Gastroenterology (AEG) and the International Association of Pancreatology (IAP); these associations shared the project with their members and through their social networks, calling for researchers and centers to join this initiative. PAN-PROMISE has also a webpage www.promisepancreatitis.com to promote center recruitment.
2.3 Patient registry PAN-PROMISE measurement will rely on a patient registry hosted in the Spanish Association of Gastroenterology (AEG) REDCap node. AEG offered this REDCap web-based online patient registry tool at no cost. Claudia Sánchez-Marin, a gastroenterologist, is on charge of quality control (data validation, data checks, contact with researchers to solve issues). The REDCap online registry was designed with logical rules to ensure good quality data entry, including mandatory fields to enter, logical ranges for quantitative variables, alarms if logical rules are not coherent (for example to have persistent organ failure but to classify the episode as mild or moderate), expanding fields only available in the presence of certain circumstances (for example, detailed organ failure description is only available if the patient had organ failure).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Month
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Consecutive patients admitted with acute pancreatitis in the participating centers.
Key inclusion criteria (4 listed)
- Patients ≥18 and <80 years.
- Karnofsky performance status previous to AP 100 (normal, no complaints, no evidence of disease), 90 (able to carry on normal activity; minor signs or symptoms of disease) or 80 (normal activity with effort; some signs or symptoms of disease).
- Acute pancreatitis defined as at least 2 of the following 3 criteria: A) Typical abdominal pain, B) Elevation of amylase and/or lipase more than 3 times the upper limit of normality, and C) Imaging (preferably CT and/or MR) compatible with AP.
- Written informed consent.
Key exclusion criteria (7 listed)
- Time between onset of symptoms and presentation in the emergency room (ER) greater than 48 hours (we do not consider as onset of symptoms previous self-limited heraldic biliary pain)
- Recruitment >24h after presentation in the ER
- Karnofsky performance status previous to AP 70 (Cares for self; unable to carry on normal activity or to do active work) or less
- Inability to express or understand the instructions of the study (severe congenital or acquired intellectual deficit).
- More than 1 previous episode of AP.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications]
Time frame: Up to 15 days after hospital discharge from index hospital admission
Mild acute pancreatitis (no complications), moderately severe acute pancreatitis (local complications and/or transient (≤48h) organ failure and/or exacerbation of previous comorbidity), severe acute pancreatitis (persistent (>48h) organ failure) (see revised Atlanta classification, Banks et al, Gut 2013)
PAN-PROMISE patient reported outcome measurement instrument
Time frame: From within 24h after admission to 15 days after discharge
PROMISE SCALE (Patient-reported Outcome Scale in Acute pancreatitis) Each item is scored from 0 to 10 ( worst score in the last 24h): 0 none, 10: the highest possible intensity according to the patient 1. Pain, especially in the abdomen, chest or back 2. Abdominal distention (bloating, sensation of excess gas) 3. Difficulty eating, sensation of food being stuck in the stomach 4. Difficulty with bowel movements (constipation or straining on bowel movements) 5. Nausea and/or vomiting 6. Thirst 7. Weakness, lack of energy, fatigue, difficulty moving
11 secondary outcomes
EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30) Version 3.0
Time frame: 15 days after hospital discharge
C-reactive protein
Time frame: 48 and 72h after recruitment
Local complications (incidence of pancreatic/peripancreatic necrosis and acute peripancreatic fluid collections)
Time frame: Up to 15 days after hospital discharge from index hospital admission
Need for invasive treatment
Time frame: Up to 15 days after hospital discharge from index hospital admission
Need for nutritional support
Time frame: Up to 15 days after hospital discharge from index hospital admission
Admission in the Intensive Care Unit
Time frame: Up to 15 days after hospital discharge from index hospital admission
Hospital stay
Time frame: Up to 15 days after hospital discharge from index hospital admission
Organ failure
Time frame: Up to 15 days after hospital discharge from index hospital admission
Mortality
Time frame: Up to 15 days after hospital discharge from index hospital admission
Hospital readmission
Time frame: Up to 15 days after hospital discharge from index hospital admission
Systemic Inflammatory Response Syndrome (SIRS)
Time frame: Up to 15 days after hospital discharge from index hospital admission
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2019.
- Background: PubMed 25057539Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001. Available from http://www.ncbi.nlm.nih.gov/books/NBK222274/
- Results publication: PubMed 29672416Sternby H, Bolado F, Canaval-Zuleta HJ, Marra-Lopez C, Hernando-Alonso AI, Del-Val-Antonana A, Garcia-Rayado G, Rivera-Irigoin R, Grau-Garcia FJ, Oms L, Millastre-Bocos J, Pascual-Moreno I, Martinez-Ares D, Rodriguez-Oballe JA, Lopez-Serrano A, Ruiz-Rebollo ML, Viejo-Almanzor A, Gonzalez-de-la-Higuera B, Orive-Calzada A, Gomez-Anta I, Pamies-Guilabert J, Fernandez-Gutierrez-Del-Alamo F, Iranzo-Gonzalez-Cruz I, Perez-Munante ME, Esteba MD, Pardillos-Tome A, Zapater P, de-Madaria E. Determinants of Severity in Acute Pancreatitis: A Nation-wide Multicenter Prospective Cohort Study. Ann Surg. 2019 Aug;270(2):348-355. doi: 10.1097/SLA.0000000000002766.
- Derived from this study: PubMed 32245906de-Madaria E, Sanchez-Marin C, Carrillo I, Vege SS, Chooklin S, Bilyak A, Mejuto R, Mauriz V, Hegyi P, Marta K, Kamal A, Lauret-Brana E, Barbu ST, Nunes V, Ruiz-Rebollo ML, Garcia-Rayado G, Lozada-Hernandez EE, Pereira J, Negoi I, Espina S, Hollenbach M, Litvin A, Bolado-Concejo F, Vargas RD, Pascual-Moreno I, Singh VK, Mira JJ. Design and validation of a patient-reported outcome measure scale in acute pancreatitis: the PAN-PROMISE study. Gut. 2021 Jan;70(1):139-147. doi: 10.1136/gutjnl-2020-320729. Epub 2020 Apr 3.
- Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling ClaimsLink provided by the sponsor.
- Institute for Healthcare Improvement (IHI): The IHI Triple AimLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The whole database will be offered to the study collaborators who actively recruited patients
Related trials for Acute Pancreatitis
Recruiting
Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis
Pancreatitis, Acute
Recruiting
Timing of CHolecystectomy In Severe PAncreatitis
Acute Pancreatitis, Cholelithiasis
Not yet recruiting
Cold Water Papillary Irrigation Plus Rectal NSAIDs vs Rectal NSAIDs Alone for Post-ERCP Pancreatitis (COLD)
Post ERCP Pancreatitis, Acute Pancreatitis (AP)
RecruitingObservational study
CytOSorb TreatMent Of Critically Ill PatientS Registry
Septic Shock, Acute Respiratory Distress Syndrome
RecruitingPhase 1/2
Soy Tomato Juice to Improve Outcomes in Pancreatitis
Recurrent Acute Pancreatitis, Chronic Pancreatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
José Joaquín Mira, PsyD PhD study director
Universidad Miguel Hernandez de Elche
Enrique de-Madaria, MD PhD principal investigator
Hospital General Universitario de Alicante
26 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Pancreatitis, run by Enrique de-Madaria at 26 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 26 sites in Spain, Hungary, Portugal, Romania, United States and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications] (time frame: Up to 15 days after hospital discharge from index hospital admission). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03650062, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2019.